Compare Toronto-Dominion Bank (TD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs TransMedics Group Inc — how do they compare? Toronto-Dominion Bank trades at $121.35 (market cap $200.48B), while TransMedics Group Inc trades at $87.11 (market cap $3.10B). The key difference: Toronto-Dominion Bank is far larger — about 64.7× TransMedics Group Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TD | TMDX | |
|---|---|---|
Market Cap | $200.48B | $3.10B |
Sector | Financials | Technology |
52-Week High | $124.80 | $150.42 |
52-Week Low | $72.85 | $61.99 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD trades at $123.38, up 1.9% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive, supported by strong earnings momentum and a unanimous analyst buy/hold consensus with no sell ratings. Key risks include volatile cash flows from operations and high leverage, with total liabilities of $1.95 trillion. The stock offers value with a P/E of 19.88 and robust profitability metrics like ROE of 12.59%.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
